Adhera Therapeutics and Alyvant strike deal for Prestalia

Adhera Therapeutics (OTCQB: ATRX), a specialty pharmaceutical firm previously known as Marina Biotech, and Alyvant, a Roivant Sciences company focused on tech-enabled pharma commercialization, yesterday announced a digital co-promotion agreement for Prestalia (perindopril arginine and amlodipine) therapy for the treatment of hypertension.

News of the deal saw Adhera’s shares drop 7.96% to $0.36.

Prestalia, which was developed by France’s largest independent pharma company Servier, was approved by the US FDA for the treatment of hypertension to lower blood pressure in 2015, when it was licensed to US drugmaker Symplmed Pharmaceuticals.

Robert Moscato Jr, chief executive of Adhera Therapeutics, commented: “We are pleased to enter into a co-promotion agreement with Alyvant. The agreement affords Adhera the opportunity to increase the frequency of communication to healthcare providers and educate physicians beyond the reach of our sales team. Alyvant is a likeminded, data-driven company, and working together on Prestalia supports Adhera’s mission of increasing drug adherence amongst our patients. We are delighted that Alyvant is co-promoting Prestalia and connecting patients to therapies that may benefit them through innovative uses of data and technology.”

Gillian Cannon, president of Alyvant, added: “We are excited to partner with Adhera Therapeutics. Adhera’s patient-centric treatment approach aligns well with Alyvant’s targeted patient-level analytics approach. We anticipate the digital co-promotion will have a positive impact on the commercialization of Prestalia, and most importantly patients at risk of cardiovascular events who would benefit from taking this therapy.”